西藏药业
(600211)
| 流通市值：136.15亿 | | | 总市值：136.15亿 |
| 流通股本：3.22亿 | | | 总股本：3.22亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 723,548,218.03 | 2,981,538,230.43 | 2,089,270,909.97 | 1,650,705,155.36 |
| 营业收入 | 723,548,218.03 | 2,981,538,230.43 | 2,089,270,909.97 | 1,650,705,155.36 |
| 二、营业总成本 | 502,684,914.58 | 1,988,734,371.46 | 1,324,837,999.8 | 1,032,761,299.84 |
| 营业成本 | 51,375,631.14 | 172,474,862.95 | 130,924,187.7 | 89,115,752.32 |
| 税金及附加 | 6,535,638.56 | 37,716,162.15 | 25,803,218.07 | 21,804,929.77 |
| 销售费用 | 395,451,437.34 | 1,644,299,989.97 | 1,124,471,808.22 | 903,033,745.96 |
| 管理费用 | 30,299,367.1 | 129,241,359.43 | 79,173,585.43 | 52,433,245.59 |
| 研发费用 | 26,475,856.6 | 74,080,120 | 28,119,542.03 | 18,772,225.08 |
| 财务费用 | -7,453,016.17 | -69,078,123.04 | -63,654,341.65 | -52,398,598.88 |
| 其中:利息费用 | 10,149,635.36 | 12,569,466.82 | 2,191,712.98 | 136,257.56 |
| 其中:利息收入 | 17,792,064.62 | 80,518,694.59 | 64,183,251.28 | 50,569,771.93 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -2,141,871.87 | 1,661,657.85 | -416,769.64 | -821,339.67 |
| 加:投资收益 | 1,446,799.23 | 7,481,444.41 | 6,450,216.3 | 5,203,734.88 |
| 资产处置收益 | 1,167.97 | 108,677.06 | 26,109.35 | 69,267.28 |
| 资产减值损失(新) | -173,718.59 | -4,845,488 | -620,925.49 | -620,925.49 |
| 信用减值损失(新) | - | 436,451.69 | -767,507.31 | -769,395.66 |
| 其他收益 | 96,301,242.56 | 46,185,366.49 | 42,780,798.14 | 17,685,768.3 |
| 营业利润平衡项目 | -0.01 | 0 | 0 | 0 |
| 四、营业利润 | 316,296,922.74 | 1,043,831,968.47 | 811,884,831.52 | 638,690,965.16 |
| 加:营业外收入 | 1,086,891.96 | 329,765.49 | 246,944.84 | 190,948.7 |
| 减:营业外支出 | 746,827.18 | 3,543,864.76 | 1,677,890.94 | 1,561,480.32 |
| 五、利润总额 | 316,636,987.52 | 1,040,617,869.2 | 810,453,885.42 | 637,320,433.54 |
| 减:所得税费用 | 33,803,518.58 | 123,636,913.48 | 84,547,034.04 | 66,531,557.65 |
| 六、净利润 | 282,833,468.95 | 916,980,955.72 | 725,906,851.38 | 570,788,875.89 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 282,833,468.95 | 916,980,955.72 | 725,906,851.38 | 570,788,875.89 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 298,709,306.88 | 937,931,435.32 | 721,777,210.07 | 567,323,117.52 |
| 少数股东损益 | -15,875,837.93 | -20,950,479.6 | 4,129,641.31 | 3,465,758.37 |
| 扣除非经常损益后的净利润 | 212,068,158.06 | 871,408,061.7 | 668,189,330.2 | 542,843,268.89 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.93 | 2.91 | 2.24 | 1.76 |
| (二)稀释每股收益 | 0.93 | 2.91 | 2.24 | 1.76 |
| 八、其他综合收益 | -12,073,799.08 | -17,441,769.97 | -13,885,663.2 | -4,937,939.25 |
| 归属于母公司股东的其他综合收益 | -12,073,799.08 | -18,051,964.49 | -13,885,663.2 | -4,937,939.25 |
| 九、综合收益总额 | 270,759,669.87 | 899,539,185.75 | 712,021,188.18 | 565,850,936.64 |
| 归属于母公司股东的综合收益总额 | 286,635,507.8 | 919,879,470.83 | 707,891,546.87 | 562,385,178.27 |
| 归属于少数股东的综合收益总额 | -15,875,837.93 | -20,340,285.08 | 4,129,641.31 | 3,465,758.37 |
| 公告日期 | 2026-04-29 | 2026-03-13 | 2025-10-31 | 2025-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |